EGFR and non-small cell lung carcinoma: Discovery of driving genes such as EGFR mutation (mainly exon 19 Del and exon 21L858R), and development of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib (Mok et al., 2009; Fukuoka et al., 2011), erlotinib (Zhou et al., 2011; Rosell et al., 2012), and icotinib (Shi et al., 2013; Shi et al., 2017), have significantly improved prognosis of advanced NSCLC patients harboring EGFR sensitizing mutation.